Annovis Bio, Inc. (ANVS)
1.70
+0.01
(+0.59%)
USD |
NYSE |
Sep 02, 16:00
1.64
-0.06
(-3.53%)
Pre-Market: 07:32
Annovis Bio Shareholders Equity (Quarterly) : -4.255M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -4.255M |
| March 31, 2026 | 3.126M |
| December 31, 2025 | 16.85M |
| September 30, 2025 | 13.16M |
| June 30, 2025 | 18.33M |
| March 31, 2025 | 24.05M |
| December 31, 2024 | 9.308M |
| September 30, 2024 | 7.064M |
| June 30, 2024 | -1.751M |
| March 31, 2024 | -3.354M |
| December 31, 2023 | -7.751M |
| September 30, 2023 | 6.658M |
| June 30, 2023 | 20.74M |
| March 31, 2023 | 20.14M |
| December 31, 2022 | 28.32M |
| September 30, 2022 | 29.96M |
| Date | Value |
|---|---|
| June 30, 2022 | 35.23M |
| March 31, 2022 | 42.04M |
| December 31, 2021 | 44.50M |
| September 30, 2021 | 46.53M |
| June 30, 2021 | 48.61M |
| March 31, 2021 | 4.368M |
| December 31, 2020 | 7.541M |
| September 30, 2020 | 9.121M |
| June 30, 2020 | 9.498M |
| March 31, 2020 | 10.69M |
| December 31, 2019 | -1.499M |
| September 30, 2019 | -1.298M |
| June 30, 2019 | -1.044M |
| March 31, 2019 | -0.699M |
| December 31, 2018 | -0.517M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 22.04M |
| Total Liabilities (Quarterly) | 26.29M |
| Current Ratio | 3.466 |